array(40) {
  [0]=>
  string(4) "9098"
  ["article_id"]=>
  string(4) "9098"
  [1]=>
  string(116) "Bayer’s Elinzanetant Meets All Primary and Key Secondary Endpoints in Pivotal OASIS 1 and 2 Phase III Studies"
  ["article_title"]=>
  string(116) "Bayer’s Elinzanetant Meets All Primary and Key Secondary Endpoints in Pivotal OASIS 1 and 2 Phase III Studies"
  [2]=>
  string(150) "Berlin, January 8, 2024 – Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy"
  ["short_description"]=>
  string(150) "Berlin, January 8, 2024 – Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy"
  [3]=>
  string(251) "Berlin, January 8, 2024 – Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully..."
  ["description"]=>
  string(251) "Berlin, January 8, 2024 – Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(147) "https://www.drugs.com/clinical_trials/bayer-s-elinzanetant-meets-all-primary-key-secondary-endpoints-pivotal-oasis-1-2-phase-iii-studies-21261.html"
  ["blog_url"]=>
  string(147) "https://www.drugs.com/clinical_trials/bayer-s-elinzanetant-meets-all-primary-key-secondary-endpoints-pivotal-oasis-1-2-phase-iii-studies-21261.html"
  [15]=>
  string(19) "2024-01-09 05:01:44"
  ["add_date"]=>
  string(19) "2024-01-09 05:01:44"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9099"
  ["article_id"]=>
  string(4) "9099"
  [1]=>
  string(71) "Residential Addiction Treatment for Adolescents is Scarce and Expensive"
  ["article_title"]=>
  string(71) "Residential Addiction Treatment for Adolescents is Scarce and Expensive"
  [2]=>
  string(150) "January 8, 2024 -- Access to residential addiction treatment centers caring for U.S. adolescents under 18 years old in the United States is limited an"
  ["short_description"]=>
  string(150) "January 8, 2024 -- Access to residential addiction treatment centers caring for U.S. adolescents under 18 years old in the United States is limited an"
  [3]=>
  string(247) "January 8, 2024 -- Access to residential addiction treatment centers caring for U.S. adolescents under 18 years old in the United States is limited and costly, according to a new study supported by the National Institutes of Health. Researchers..."
  ["description"]=>
  string(247) "January 8, 2024 -- Access to residential addiction treatment centers caring for U.S. adolescents under 18 years old in the United States is limited and costly, according to a new study supported by the National Institutes of Health. Researchers..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(89) "https://www.drugs.com/clinical_trials/residential-adolescents-scarce-expensive-21259.html"
  ["blog_url"]=>
  string(89) "https://www.drugs.com/clinical_trials/residential-adolescents-scarce-expensive-21259.html"
  [15]=>
  string(19) "2024-01-09 05:01:14"
  ["add_date"]=>
  string(19) "2024-01-09 05:01:14"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9069"
  ["article_id"]=>
  string(4) "9069"
  [1]=>
  string(78) "Astellas Provides Update on Zolbetuximab Biologics License Application in U.S."
  ["article_title"]=>
  string(78) "Astellas Provides Update on Zolbetuximab Biologics License Application in U.S."
  [2]=>
  string(158) "TOKYO, Jan. 8, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and D"
  ["short_description"]=>
  string(158) "TOKYO, Jan. 8, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and D"
  [3]=>
  string(253) "TOKYO, Jan. 8, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) issued a complete response letter on January 4, 2024, regarding the..."
  ["description"]=>
  string(253) "TOKYO, Jan. 8, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) issued a complete response letter on January 4, 2024, regarding the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(50) "https://www.drugs.com/nda/zolbetuximab_240108.html"
  ["blog_url"]=>
  string(50) "https://www.drugs.com/nda/zolbetuximab_240108.html"
  [15]=>
  string(19) "2024-01-09 04:01:42"
  ["add_date"]=>
  string(19) "2024-01-09 04:01:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9100"
  ["article_id"]=>
  string(4) "9100"
  [1]=>
  string(144) "Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3"
  ["article_title"]=>
  string(144) "Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3"
  [2]=>
  string(150) "NORTH CHICAGO, Ill., Jan. 8, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced Phase 2 results showing adults with moderate to severe hidradeni"
  ["short_description"]=>
  string(150) "NORTH CHICAGO, Ill., Jan. 8, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced Phase 2 results showing adults with moderate to severe hidradeni"
  [3]=>
  string(251) "NORTH CHICAGO, Ill., Jan. 8, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced Phase 2 results showing adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981)..."
  ["description"]=>
  string(251) "NORTH CHICAGO, Ill., Jan. 8, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced Phase 2 results showing adults with moderate to severe hidradenitis suppurativa (HS) who had previously failed anti-TNF therapy who received lutikizumab (ABT-981)..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(146) "https://www.drugs.com/clinical_trials/lutikizumab-showed-positive-results-phase-2-trial-adults-moderate-severe-hidradenitis-suppurativa-21257.html"
  ["blog_url"]=>
  string(146) "https://www.drugs.com/clinical_trials/lutikizumab-showed-positive-results-phase-2-trial-adults-moderate-severe-hidradenitis-suppurativa-21257.html"
  [15]=>
  string(19) "2024-01-09 04:01:33"
  ["add_date"]=>
  string(19) "2024-01-09 04:01:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9101"
  ["article_id"]=>
  string(4) "9101"
  [1]=>
  string(98) "FDA Approves Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma"
  ["article_title"]=>
  string(98) "FDA Approves Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma"
  [2]=>
  string(162) "ROCKVILLE, Md., Jan. 8, 2024. Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to"
  ["short_description"]=>
  string(162) "ROCKVILLE, Md., Jan. 8, 2024. Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to"
  [3]=>
  string(272) "ROCKVILLE, Md., Jan. 8, 2024. Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to Proceed' letter from the U.S. Food and Drug Administration (FDA) for the Company's investigational..."
  ["description"]=>
  string(272) "ROCKVILLE, Md., Jan. 8, 2024. Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to Proceed' letter from the U.S. Food and Drug Administration (FDA) for the Company's investigational..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(122) "https://www.drugs.com/clinical_trials/fda-approves-phase-ii-clinical-trial-ropidoxuridine-patients-glioblastoma-21256.html"
  ["blog_url"]=>
  string(122) "https://www.drugs.com/clinical_trials/fda-approves-phase-ii-clinical-trial-ropidoxuridine-patients-glioblastoma-21256.html"
  [15]=>
  string(19) "2024-01-09 04:01:26"
  ["add_date"]=>
  string(19) "2024-01-09 04:01:26"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9241"
  ["article_id"]=>
  string(4) "9241"
  [1]=>
  string(65) "UpDoc to develop conversational, assistant-directed AI providers "
  ["article_title"]=>
  string(65) "UpDoc to develop conversational, assistant-directed AI providers "
  [2]=>
  string(150) "Microsoft, Google, the Santa Clara County Independent Physician Association, UCSF Health, Mayo Clinic and the American Heart Association are partnerin"
  ["short_description"]=>
  string(150) "Microsoft, Google, the Santa Clara County Independent Physician Association, UCSF Health, Mayo Clinic and the American Heart Association are partnerin"
  [3]=>
  string(250) "Microsoft, Google, the Santa Clara County Independent Physician Association, UCSF Health, Mayo Clinic and the American Heart Association are partnering with the company to put clinically managed artificial intelligence providers in patient homes.&#nl"
  ["description"]=>
  string(250) "Microsoft, Google, the Santa Clara County Independent Physician Association, UCSF Health, Mayo Clinic and the American Heart Association are partnering with the company to put clinically managed artificial intelligence providers in patient homes.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(98) "https://www.healthcareitnews.com/news/updoc-develop-conversational-assistant-directed-ai-providers"
  ["blog_url"]=>
  string(98) "https://www.healthcareitnews.com/news/updoc-develop-conversational-assistant-directed-ai-providers"
  [15]=>
  string(19) "2024-01-09 00:22:21"
  ["add_date"]=>
  string(19) "2024-01-09 00:22:21"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9242"
  ["article_id"]=>
  string(4) "9242"
  [1]=>
  string(69) "Vanderbilt piloting Nuance DAX Copilot, testing other genAI use cases"
  ["article_title"]=>
  string(69) "Vanderbilt piloting Nuance DAX Copilot, testing other genAI use cases"
  [2]=>
  string(164) "The projects mark a "significant step in VUMC’s exploration of AI’s potential in streamlining clinician workflows and enhancing medical record-kee"
  ["short_description"]=>
  string(164) "The projects mark a "significant step in VUMC’s exploration of AI’s potential in streamlining clinician workflows and enhancing medical record-kee"
  [3]=>
  string(256) "The projects mark a "significant step in VUMC’s exploration of AI’s potential in streamlining clinician workflows and enhancing medical record-keeping while reducing time spent on documentation," said the health system's CMIO.&#nl"
  ["description"]=>
  string(256) "The projects mark a "significant step in VUMC’s exploration of AI’s potential in streamlining clinician workflows and enhancing medical record-keeping while reducing time spent on documentation," said the health system's CMIO.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(106) "https://www.healthcareitnews.com/news/vanderbilt-piloting-nuance-dax-copilot-testing-other-genai-use-cases"
  ["blog_url"]=>
  string(106) "https://www.healthcareitnews.com/news/vanderbilt-piloting-nuance-dax-copilot-testing-other-genai-use-cases"
  [15]=>
  string(19) "2024-01-08 23:47:16"
  ["add_date"]=>
  string(19) "2024-01-08 23:47:16"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9152"
  ["article_id"]=>
  string(4) "9152"
  [1]=>
  string(68) "Accanto Health appoints seasoned behavioral healthcare leader as CEO"
  ["article_title"]=>
  string(68) "Accanto Health appoints seasoned behavioral healthcare leader as CEO"
  [2]=>
  string(150) "Dr. Tom Britton will focus on driving growth and accessibility of treatment for people with eating disorders and related conditions using a compassion"
  ["short_description"]=>
  string(150) "Dr. Tom Britton will focus on driving growth and accessibility of treatment for people with eating disorders and related conditions using a compassion"
  [3]=>
  string(368) "Dr. Tom Britton will focus on driving growth and accessibility of treatment for people with eating disorders and related conditions using a compassionate, evidence-based approach 
Dr. Tom Britton will focus on driving growth and accessibility of treatment for people with eating disorders and related conditions using a compassionate, evidence-based approach
"
  ["description"]=>
  string(368) "Dr. Tom Britton will focus on driving growth and accessibility of treatment for people with eating disorders and related conditions using a compassionate, evidence-based approach 
Dr. Tom Britton will focus on driving growth and accessibility of treatment for people with eating disorders and related conditions using a compassionate, evidence-based approach
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(140) "https://www.globenewswire.com/news-release/2024/01/08/2805561/0/en/Accanto-Health-appoints-seasoned-behavioral-healthcare-leader-as-CEO.html"
  ["blog_url"]=>
  string(140) "https://www.globenewswire.com/news-release/2024/01/08/2805561/0/en/Accanto-Health-appoints-seasoned-behavioral-healthcare-leader-as-CEO.html"
  [15]=>
  string(19) "2024-01-08 22:15:00"
  ["add_date"]=>
  string(19) "2024-01-08 22:15:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9158"
  ["article_id"]=>
  string(4) "9158"
  [1]=>
  string(79) "SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023"
  ["article_title"]=>
  string(79) "SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023"
  [2]=>
  string(150) "Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30% Fiscal Year 2023 revenue of $138.5 - $138.7 million representing g"
  ["short_description"]=>
  string(150) "Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30% Fiscal Year 2023 revenue of $138.5 - $138.7 million representing g"
  [3]=>
  string(178) "Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30% 
Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30%
"
  ["description"]=>
  string(178) "Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30% 
Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30%
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(151) "https://www.globenewswire.com/news-release/2024/01/08/2805458/0/en/SI-BONE-Announces-Preliminary-Revenue-for-the-Fourth-Quarter-and-Full-Year-2023.html"
  ["blog_url"]=>
  string(151) "https://www.globenewswire.com/news-release/2024/01/08/2805458/0/en/SI-BONE-Announces-Preliminary-Revenue-for-the-Fourth-Quarter-and-Full-Year-2023.html"
  [15]=>
  string(19) "2024-01-08 21:30:00"
  ["add_date"]=>
  string(19) "2024-01-08 21:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:30"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:30"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9153"
  ["article_id"]=>
  string(4) "9153"
  [1]=>
  string(106) "Surgery Partners, Inc. Reaffirms 2023 Full Year Guidance and Provides 2024 Initial Adjusted EBITDA Outlook"
  ["article_title"]=>
  string(106) "Surgery Partners, Inc. Reaffirms 2023 Full Year Guidance and Provides 2024 Initial Adjusted EBITDA Outlook"
  [2]=>
  string(162) "BRENTWOOD, Tenn., Jan.  08, 2024  (GLOBE NEWSWIRE) --  Members of management of Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Compa"
  ["short_description"]=>
  string(162) "BRENTWOOD, Tenn., Jan.  08, 2024  (GLOBE NEWSWIRE) --  Members of management of Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Compa"
  [3]=>
  string(749) "
BRENTWOOD, Tenn., Jan.  08, 2024  (GLOBE NEWSWIRE) --  Members of management of Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, will be meeting with investors today, January 8, 2024, as part of the 42nd Annual J.P. Morgan Healthcare Conference, including a presentation at 5:15 p.m. ET. Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion. Additionally, consistent with managements commitment to driving mid-teens growth, the Company projects 2024 Adjusted EBITDA to be greater than $495 million.
"
  ["description"]=>
  string(749) "
BRENTWOOD, Tenn., Jan.  08, 2024  (GLOBE NEWSWIRE) --  Members of management of Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, will be meeting with investors today, January 8, 2024, as part of the 42nd Annual J.P. Morgan Healthcare Conference, including a presentation at 5:15 p.m. ET. Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion. Additionally, consistent with managements commitment to driving mid-teens growth, the Company projects 2024 Adjusted EBITDA to be greater than $495 million.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(180) "https://www.globenewswire.com/news-release/2024/01/08/2805331/36929/en/Surgery-Partners-Inc-Reaffirms-2023-Full-Year-Guidance-and-Provides-2024-Initial-Adjusted-EBITDA-Outlook.html"
  ["blog_url"]=>
  string(180) "https://www.globenewswire.com/news-release/2024/01/08/2805331/36929/en/Surgery-Partners-Inc-Reaffirms-2023-Full-Year-Guidance-and-Provides-2024-Initial-Adjusted-EBITDA-Outlook.html"
  [15]=>
  string(19) "2024-01-08 20:30:00"
  ["add_date"]=>
  string(19) "2024-01-08 20:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9154"
  ["article_id"]=>
  string(4) "9154"
  [1]=>
  string(120) "Option Care Health Selects Palantir’s Artificial Intelligence Platform for Enterprise-Wide Digital Transformation"
  ["article_title"]=>
  string(120) "Option Care Health Selects Palantir’s Artificial Intelligence Platform for Enterprise-Wide Digital Transformation"
  [2]=>
  string(150) "DENVER and BANNOCKBURN, Ill., Jan.  08, 2024  (GLOBE NEWSWIRE) -- Palantir Technologies Inc. (NYSE: PLTR), a leading provider of AI systems, and Optio"
  ["short_description"]=>
  string(150) "DENVER and BANNOCKBURN, Ill., Jan.  08, 2024  (GLOBE NEWSWIRE) -- Palantir Technologies Inc. (NYSE: PLTR), a leading provider of AI systems, and Optio"
  [3]=>
  string(506) "
DENVER and BANNOCKBURN, Ill., Jan.  08, 2024  (GLOBE NEWSWIRE) -- Palantir Technologies Inc. (NYSE: PLTR), a leading provider of AI systems, and Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, today announced a multi-year commercial partnership for Palantir’s software to be leveraged across the company to help improve patient outcomes and increase efficiency.
"
  ["description"]=>
  string(506) "
DENVER and BANNOCKBURN, Ill., Jan.  08, 2024  (GLOBE NEWSWIRE) -- Palantir Technologies Inc. (NYSE: PLTR), a leading provider of AI systems, and Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, today announced a multi-year commercial partnership for Palantir’s software to be leveraged across the company to help improve patient outcomes and increase efficiency.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(185) "https://www.globenewswire.com/news-release/2024/01/08/2805281/0/en/Option-Care-Health-Selects-Palantir-s-Artificial-Intelligence-Platform-for-Enterprise-Wide-Digital-Transformation.html"
  ["blog_url"]=>
  string(185) "https://www.globenewswire.com/news-release/2024/01/08/2805281/0/en/Option-Care-Health-Selects-Palantir-s-Artificial-Intelligence-Platform-for-Enterprise-Wide-Digital-Transformation.html"
  [15]=>
  string(19) "2024-01-08 20:00:00"
  ["add_date"]=>
  string(19) "2024-01-08 20:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9314"
  ["article_id"]=>
  string(4) "9314"
  [1]=>
  string(69) "Most extensive cirrhosis £30M study funded by Boehringer Ingelheim"
  ["article_title"]=>
  string(69) "Most extensive cirrhosis £30M study funded by Boehringer Ingelheim"
  [2]=>
  string(153) "A Â30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and Un"
  ["short_description"]=>
  string(153) "A Â30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and Un"
  [3]=>
  string(207) "A Â30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim."
  ["description"]=>
  string(207) "A Â30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(164) "https://www.outsourcing-pharma.com/Article/2024/01/08/extensive-30-million-38-million-study-into-liver-cirrhosis?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(164) "https://www.outsourcing-pharma.com/Article/2024/01/08/extensive-30-million-38-million-study-into-liver-cirrhosis?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-08 19:16:00"
  ["add_date"]=>
  string(19) "2024-01-08 19:16:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:36"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}